We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


TET Systems and SIRION BIOTECH Sign a Commercial License Agreement

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TET Systems and SIRION BIOTECH Sign a Commercial License Agreement"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
TET Systems (TET) and SIRION BIOTECH GmbH, two privately-held, German biotech companies based in Heidelberg and Martinsried near Munich, respectively, announced that they have signed a commercial license agreement.

Under the terms of the agreement, SIRION BIOTECH offers customized services to its clients using the Tet Technology to generate cell lines and to generate and manufacture recombinant viral vector products.

“We are very pleased to sign this commercial license agreement with SIRION BIOTECH. The services offered by SIRION BIOTECH, in particular the recombinant adenoviral production services, have not been available through our existing Authorized Partner Network and SIRION BIOTECH’S addition nicely complements our existing network. Since there has been demand in the past for these services from our existing licensees and academic institutions we expect that this new agreement will be the basis for a successful business relationship with SIRION BIOTECH,” stated Dr. Ernst Boehnlein, CEO of TET Systems. “We will continue to add to our Partner Network to fill existing gaps, to accommodate our customers` demands and to make new technologies available to our licensees.”

The license of the Tet Technology allows SIRION BIOTECH to switch on or turn off the induced gene products in genetically modified cells. The use of this technology expands the services of the company and helps to circumvent the disadvantages of traditional genetically modified cells with permanent gene expression. The Tet Technology leads to a broader application range of SIRION BIOTECH vectors. Hence Pharma and Biotech customers are able to achieve better results in screening and providing higher success rates in target validation.

“With the licensing of the Tet Technology we are broadening our customer`s benefits fundamentally and therefore have added a substantial revenue driver to the services we already offer,” said Dr. Christian Thirion, CSO of SIRION BIOTECH.